Related Experiment Video
Updated: Jul 8, 2026

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis
Published on: March 14, 2025
Clinical management of EGFRI dermatologic toxicities: the Japanese perspective
1Dermatology Division, National Cancer Center Hospital, Tokyo, Japan. nyamazak@ncc.go.jp
Abstract:
Epidermal growth factor receptor inhibitors (EGFRIs) have demonstrated clinical activity in patients with non-small-cell lung cancer, pancreatic cancer, and colorectal cancer. EGFRIs are generally well tolerated, but reversible dermatologic toxicities are commonly associated with their use. Limited clinical evidence has characterized these adverse reactions as a class effect. For panitumumab (Vectibix), mild-to-moderate dermatologic toxicities are the most common associated adverse reactions. This report details the Japanese experience in the management of dermatologic toxicities associated with panitumumab use. Treatment selection for skin toxicity in Japan is also detailed, with a flowchart depicting strategies to treat various stages of dermatologic toxicities. Panitumumab was well tolerated in Japanese patients with advanced solid tumors, with a safety profile similar to that seen in non-Japanese patients.
Related Concept Videos
Clinical Applications of Epidermal Stem Cells
Drug Toxicity: Allergic Reactions
Nephrotic Syndrome III : Nursing Management
Changes in Skin Color: Clinical Perspectives
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
Pharmaceutical Poisoning: Treatment Strategies
Prevention of Further Absorption of Poison